argenx SE (ARGX) PT Raised to $707 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall Street ends down as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil settles up around 4% as Iran's president vows to never surrender
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- On Holding sets 2029 financial targets, authorizes $1B share buyback
- Nasdaq reaches record high close, AI stocks rally
- Elmet Group signs tungsten offtake deal with Hemerdon Mine
- Meta bull case increasingly playing out, Mizuho says
argenx SE (ARGX) PT Raised to $675 at Oppenheimer
November 21, 2024 5:08 AM ESTOppenheimer analyst Leland Gershell raised the price target on argenx SE (NASDAQ: ARGX) to $675.00 (from $646.00) while maintaining a Outperform rating.
The analyst comments "Yesterday ARGX announced clinical proof-of-concept in myositis, with subQ efgart yielding statistically-significant improvement across all three myositis subtypes being evaluated in... More
argenx SE (ARGX:BB) (ARGX) PT Raised to EUR670 at Barclays
November 21, 2024 1:34 AM ESTBarclays analyst Charles Pitman-King raised the price target on argenx SE (ARGX:BB) (NASDAQ: ARGX) to EUR670.00 (from EUR650.00) while maintaining a Overweight rating.
The analyst comments: "Following the positive GO decision from the P2 analysis of the ongoing P2/3 ALKIVIA trial, noting... More
argenx SE (ARGX) PT Raised to $706 at Evercore ISI
November 20, 2024 3:57 PM ESTEvercore ISI analyst Gavin Clark-Gartner raised the price target on argenx SE (NASDAQ: ARGX) to $706.00 (from $675.00) while maintaining a Outperform rating.
... MoreLate Morning $5 Dip in argenx SE (ARGX) Attributed to Raymond James Comments, 'we are introducing the myositis opportunity into our model'
November 20, 2024 11:44 AM ESTRaymond James analyst Danielle Brill raised the price target on argenx SE (NASDAQ: ARGX) to $770.00 (from $688.00) while maintaining a Strong Buy rating.
The analyst comments "This morning, ARGX announced their plans to advance development of efgartigimod (SC) into Phase 3 for myositis. The Go decision... More
